长周期通常是因为提供商未能基于38,000名归属患者的每期成本建立内部理由，而非销售方未能说服。 医疗服务提供商面临的问题版本并非通用版本。已对38,000名患者承担下行风险，却缺少定价所需的每期成本数据——忽略每期成本的答案必然错误。分析必须从付款人组合和患者面板规模入手，而非从收入入手。
长周期通常是因为提供商未能基于38,000名归属患者的每期成本建立内部理由，而非销售方未能说服。 医疗服务提供商面临的问题版本并非通用版本。已对38,000名患者承担下行风险，却缺少定价所需的每期成本数据——忽略每期成本的答案必然错误。分析必须从付款人组合和患者面板规模入手，而非从收入入手。
周期过长很少是因为对基于价值的合同缺乏兴趣。它停滞在特定阶段——交易持续滞留的阶段——而这个点通常是 champion 需要向 CFO 或医务主任说明面板规模和付款人组合决策时，后者从未参与讨论。
这重新定义了解决方式。缩短周期主要是给 champion 提供在你不在场的情况下赢得争论的材料：每期成本预测、针对下行风险的应对、与当前付款人组合下不作为的对比。
另一个常见原因是向无权批准基于价值合同支出的人销售。这不会显著延长周期，而是会在最后增加一个隐藏周期。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 机会在同一阶段停留数周，没有更新后的每期成本模型送达 CFO 或医务主任。
✓ 与基于价值合同下归属患者相关的同一机会，预测日期反复推迟。
✓ 在已审阅每提供商贡献后，输掉的交易中主要竞争对手是基于价值合同的“不做决定”。
通常会让情况更糟的做法。 增加跟进活动，这加大了 champion 的压力，却没有提供新材料带给决策者用于每期成本讨论。
It is for you if you run or finance a healthcare provider and deals consistently stall at the same stage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
找出交易停留最长的阶段，明确买方在那里必须做什么。那几乎总是内部审批，解决办法是提供材料而非说服。
这只会压缩最后一步，对周期早期停滞毫无作用，而时间实际耗在那里。它还会让买方学会等待有回报。
不是，如果交易规模和成交率能证明合理。当周期长于现金周转允许时，它才成为问题，这是融资约束而非销售问题。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית